On the other hand, BabySat is a prescription device that integrates medical-grade pulse oximetry technology into a discreet wearable. It provides noninvasive measurement of oxygen circulation to extremities in infants aged 1 to 18 months. As the first device of its kind to receive FDA approval, it stands apart from other non-prescription medical-grade alternatives. The availability of BabySat with a prescription is particularly valuable for parents whose babies have been diagnosed with heart defects or chronic conditions. Prompt intervention by medical professionals is crucial if a newborn or baby exhibits persistent low oxygen levels to prevent potentially life-threatening complications.
